Literature DB >> 20618628

Evaluation of platelet activation in canine immune-mediated haemolytic anaemia.

A E Ridyard1, D J Shaw, E M Milne.   

Abstract

OBJECTIVES: To establish whether heightened platelet activation is a common feature of canine immune-mediated haemolytic anaemia, and to evaluate the hypothesis that platelet activation plays a role in the pathogenesis of thromboembolism.
METHODS: Using whole-blood flow-cytometric analysis, the proportion of activated platelets and platelet-leucocyte aggregates in blood samples from 14 dogs with immune-mediated haemolytic anaemia and 14 healthy dogs was calculated. General linear models with binomial errors were used to compare groups. Results from the immune-mediated haemolytic anaemia-affected dogs were then correlated with established risk factors for thromboembolism in canine immune-mediated haemolytic anaemia, D-dimer concentration and antithrombin activity.
RESULTS: There was a strong correlation between platelet activation and severe thrombocytopenia, with heightened platelet activation being observed predominantly in severely thrombocytopenic dogs. CLINICAL SIGNIFICANCE: Dogs with immune-mediated haemolytic anaemia, particularly those with concurrent severe thrombocytopenia, are likely to have heightened platelet activation, which may play a role in the pathogenesis of thromboembolism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20618628     DOI: 10.1111/j.1748-5827.2010.00935.x

Source DB:  PubMed          Journal:  J Small Anim Pract        ISSN: 0022-4510            Impact factor:   1.522


  4 in total

1.  Whole blood platelet impedance aggregometry with the ROTEM platelet device: comparison of 2 anticoagulants and storage times for the establishment of canine reference intervals.

Authors:  Lara M Heimgartner; Martina Stirn; Annette P N Kutter; Nadja E Sigrist; Rahel Jud Schefer
Journal:  J Vet Diagn Invest       Date:  2021-10-15       Impact factor: 1.569

2.  Procoagulant microparticles in dogs with immune-mediated hemolytic anemia.

Authors:  L Kidd; J Geddings; Y Hisada; M Sueda; T Concannon; T Nichols; E Merricks; N Mackman
Journal:  J Vet Intern Med       Date:  2015-04-13       Impact factor: 3.333

3.  ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs.

Authors:  James W Swann; Oliver A Garden; Claire L Fellman; Barbara Glanemann; Robert Goggs; Dana N LeVine; Andrew J Mackin; Nathaniel T Whitley
Journal:  J Vet Intern Med       Date:  2019-03-07       Impact factor: 3.333

4.  Urinary 11-dehydrothromboxane B2 concentrations in 20 dogs with primary immune-mediated hemolytic anemia.

Authors:  Elizabeth A Conway; Neil P Evans; Alison E Ridyard
Journal:  J Vet Intern Med       Date:  2021-12-03       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.